Efficacy of edaravone in patients with progressive ischemic stroke and its effect on plasma erythropoietin
ZHANG Jiu-de;WANG Shu-min;Department of Neurology, Huashan Central Hospital,Xi'an;Department of Pharmacy,Xi'an No.3 Hospital;
Objective To investigate the efficacy of edaravone in patients with progressive ischemic stroke and its effect on plasma erythropoietin(EPO). Methods A total of 72 cases of patients with progressive ischemic stroke in our hospitalwere divided into study group and the control group by random number table, with 36 cases in each group. On the basis of conventional symptomatic supportive therapy, the study group was treated with intravenous infusion of edaravone, and the control group received a constant volume of placebo saline intravenous infusion. The clinical efficacy, plasma EPO level and adverse drug reactions of the two group were observed before and after treatment. Results The total effective rate of the study group was 88.89%, which was significantly higher than 69.44% of the control group(P0.05). There was no significant difference in plasma EPO levels between the two groups before treatment(P0.05). The level of plasma EPO at 14 d in the study group was significantly higher than that in the control group and before treatment(P0.05). There was no obvious adverse drug reactions in the two groups during the treatment. Conclusion Edaravone is effective in the treatment of patients with progressive ischemic stroke. It can effectively improve the neurological status and the level of plasma EPO, which is suitable for clinical promotion.
【CateGory Index】： R743.3